Inavir TwinCaps launches in Japan


Daiichi Sankyo will supply four million packs by March 2011

Daiichi Sankyo Company has launched Inavir, an inhalation powder delivered by Hovione’s TwinCaps inhaler to treat influenza in Japan.

Hovione of Portugal designed TwinCaps specifically for this indication. It is licensed to Daiichi Sankyo of Japan and to Australia-based Biota Holdings.

Daiichi Sankyo has demonstrated that one 40mg dose of the Inavir active ingredient, laninamivir octanoate, is as effective as oseltamivir, a drug that requires a five-day course of treatment.

The company plans to supply the Japanese market with four million packs by end of March 2011. Half will be supplied by end of 2010.

The reimbursement price of the pack for adult treatment has been set at JPY4,161 (€36; US$50).